Send In The Senolytics

Elie Dolgin's recent article in Nature Biotechnology explains why the failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development - including work by SRF's Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

Elie Dolgin’s recent article in Nature Biotechnology explains why the apparent failure of the first senolytic drug to enter clinical trials is far from being a refutation of the senolytic hypothesis, and reviews the growing arsenal of other senolytics currently in development – including work by SRF’s Dr. Amit Sharma and SRF-supported startup Oisín Biotechnologies.

We respect your privacy. You can unsubscribe at any time.

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Send In The Senolytics

Recent Posts:

Announcing the new Chairman of the SRF Board of Directors

A Message from the SRF Board of Directors

New Peer-Reviewed Paper from SENS Research Foundation Reports a Better Method to Study How Immune Cells Seek and Destroy Senescent Cells

We are thrilled to announce the expansion of our Research Center

Michael Rae and Dr. Robert Rodgers discuss Parkinson’s and aging

SENS Research Foundation & Underdog Pharmaceuticals jointly awarded $252,000 NIA research grant

SRF’s researchers presenting our work at Indian biosciences conferences

British Daily Mirror featured an interview with SENS Research Foundation’s Science Writer Michael Rae about the world’s richest men taking on the longevity challenge

Longevity Science Foundation’s $1 billion, 10 year distribution shows shift in attitudes since SRF inception

Congratulations to our long-time collaborators: the Buck Institute, Judith Campisi and team for the new NIH grant.

NIA Reports Senolytics Show Potential to Protect Against Coronavirus in Older Mice

SENS Research Foundation wishes you Happy International Longevity Day and Longevity Month!

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can